Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-23-156728
Filing Date
2023-05-30
Accepted
2023-05-30 17:21:49
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A d480208ddefa14a.htm DEFA14A 38225
2 GRAPHIC g480208g0531020019065.jpg GRAPHIC 3014
  Complete submission text file 0001193125-23-156728.txt   43616
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

EIN.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-28386 | Film No.: 23977859
SIC: 2834 Pharmaceutical Preparations